Floatz logo

Choline Salicylate

Recurrent Histiocytic and Dendritic Cell Neoplasm

Mayo ClinicSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Recurrent Histiocytic and Dendritic Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Selpercatinib
National Cancer Institute (NCI)
Phase 2CCC
Ulixertinib
National Cancer Institute (NCI)
Phase 2CCC
PANITUMUMAB
Institut de Recherches Internationales Servier
Phase 1/2CCC
s241656
Institut de Recherches Internationales Servier
Phase 1/2CCC
s241656
Institut de Recherches Internationales Servier
Phase 1/2CCC

View all 14 →

Same molecule, other indications

Choline Salicylate is also rated in:

Hodgkins lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →